REZŪM vs. Dual Drug Therapy for Symptomatic Benign Prostatic Hyperplasia in Sexually Active Men
← catalyst calendarSponsored by Boston Scientific Corporation (industry) · BSX — their whole pipeline →.
Phase
Not applicable
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
155actual
Sites
21
Countries
Australia, France
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-09-15 | actual | When the study began enrolling |
| Primary completion | 2025-12-11 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2021-04-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Benign Prostatic Hyperplasia (BPH)
Interventions
- Device: REZŪM
- Drug: alpha blocker and 5-alpha reductase inhibitor — also filed as Dual Drug Therapy
Primary outcomes
what the primary-completion date above is the date OFInternational Prostate Symptom Score (IPSS) change
measured From Baseline to 12 months
Male Sexual Health Questionnaire (MSHQ) total score change
measured From Baseline to 12 months
Permalink · BSX's whole pipeline · Catalyst calendar · Every registered study · What changed